Q-omics provides the consensus-scored RN7SL870P profile across patient tissues and cancer cell-line models. RN7SL870P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RN7SL870P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RN7SL870P RNA expression shows 6,069 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, and STAD as cancer lineages where RN7SL870P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL870P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL870P survival associations across molecular data types. RN7SL870P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL870P RNA expression–survival associations across cancer types. High RN7SL870P expression shows unfavorable associations in MESO, BLCA, LIHC, LUAD, THYM and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RN7SL870P RNA expression.
This table summarizes RN7SL870P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL870P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL870P shows higher tumor expression in STAD. The STAD box plot shows higher RN7SL870P RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .039).
This table shows molecular features associated with RN7SL870P in patient tissues and cancer cell lines. In patient samples, RN7SL870P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
